Abvance Therapeutics
Stephen Daly is currently the Chief Operating Officer at Abvance Therapeutics since June 2023. Prior to this, Stephen held various leadership positions in companies such as RTMBio, ADOCIA, Halozyme, AFFYMAX, and Amylin Pharmaceuticals. Stephen has a background in marketing and sales, with a strong focus on the pharmaceutical industry. Stephen has also pursued education at Northeastern University and the University of Florida.
This person is not in any teams
This person is not in any offices
Abvance Therapeutics
Traditional insulin replacement therapy involves multiple daily insulin injections or the delivery of insulin by a pump, the need for careful blood glucose monitoring, and the fear of an unwanted fall in blood glucose (hypoglycemia). Fear of hypoglycemia prevents optimal glycemic management leading to long-term hyperglycemia and damage to the body (kidney, heart, extremities). Abvance is a biotechnology company developing a new insulin: glucagon formulation called ABV100 for preventing hypoglycemia. Patients who use ABV100 instead of insulin will experience improved blood glucose control with a safety buffer against hypoglycemia. In addition, ABV100 does not require new behavioral changes or devices and will lighten the daily burden of disease management. ABV100: A titratable, fixed ratio combination of two FDA-approved peptides to control glycemia while mitigating the threat of hypoglycemia.